Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT01877811
Title CEP-32496 in Patients With Advanced Solid Tumors in Phase 1 and Advanced Melanoma and Metastatic Colorectal Cancer in Phase 2
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors Teva Pharmaceutical Industries
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
City of Hope Duarte California United States Details
University of California Irvine College of Medicine Irvine California United States Details
University of California San Diego Moores Cancer Center San Diego California United States Details
Lombardi Comprehensive Cancer Center, Georgetown Washington District of Columbia United States Details
Florida Cancer Center Sarasota Florida United States Details
University Cancer & Blood Center, LLC Athens Georgia United States Details
Massachusetts General Hospital/Beth Israel Deaconess Med. Ctr./Dana Farber Cancer Institute Boston Massachusetts United States Details
Henry Ford Health System Detroit Michigan United States Details
Karmanos Cancer Center Detroit Michigan United States Details
Washington University Saint Louis Missouri United States Details
Memorial Sloan Kettering Cancer Center New York New York United States Details
Fox Chase Cancer Center Philadelphia Pennsylvania United States Details
University of Texas MD Anderson Cancer Center Houston Texas United States Details
University of Washington, Seattle Cancer Care Alliance Seattle Washington United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field